7 Point72 Asset Management Stocks With Big Sales Growth

in INVESTING IDEAS by

Clovis Oncology, Inc. (NASDAQ: CLVS) and Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) are among the high growth stocks that Steven Cohen owns based on recent SEC filings. Growth investors may want to take a closer look at the names below.


Point72 Asset Management’s Fastest Growing Stocks

Analysts often look at companies as either thriving, surviving or dying. Analyzing a company’s revenue growth can help distinguish between these stages. Growth of over 10% typically signifies the core business is doing very well and the company’s products and services are in demand.

The table below lists 7 stocks in Point72 Asset Management’s portfolio that have strong top-line growth.

Point72 Asset Management Fastest Growing Stocks
Ticker Name Revenue Growth % Of Portfolio
CLVS CLOVIS ONCOLOGY INC 840.5% 0.3%
ADMS ADAMAS PHARMACEUTICALS INC 686.9% 0.2%
ACAD ACADIA PHARMACEUTICALS INC 386.0% 0.4%
CDEV CENTENNIAL RESOURCE DEV INC 303.8% 0.2%
PTEN PATTERSON UTI ENERGY INC 200.5% 0.5%
ICUI ICU MED INC 163.7% 0.2%
XOG EXTRACTION OIL AND GAS INC 130.9% 0.2%

Clovis Oncology, Inc. (NasdaqGS: CLVS) is the fastest growing company in Point72 Asset Management’s portfolio. The company’s LTM total revenue of $67 million is up 840.5% year-over-year. Very impressive. Note that the stock price is down -48.8% over the last twelve months.

Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) appears to be the second highest growth stock in the portfolio. The company’s latest top-line improvement of 686.9% is very intriguing. With 386.0% LTM sales growth, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is the third fastest growing company in Steven Cohen’s portfolio.

Other notable growth stocks include Centennial Resource Development, Inc. (NASDAQ: CDEV), Patterson-UTI Energy, Inc. (NASDAQ: PTEN), ICU Medical, Inc. (NASDAQ: ICUI) and Extraction Oil & Gas, Inc. (NASDAQ: XOG).


Why Follow Steven Cohen’s Portfolio?

If you haven’t heard of Billionaire Steven Cohen, you may already know a little about him if you’ve watched Showtime’s hit series Billions. Damian Lewis plays the show’s main character Bobby Axelrod that very loosely portrays Cohen and his former hedge fund SAC Capital.

The show focuses on a district attorney (played by Paul Giamatti) whose sole focus is to take down Axelrod on securities fraud. Cohen’s hedge fund, SAC Capital, was similarly charged with insider trading in 2013 and ultimately settled out of court for $1.8 billion in the largest securities fraud case ever. The Showtime series is very entertaining, albeit pure entertainment, and not entirely an accurate representation of Cohen.

Investing morality aside, Cohen’s real-life results are undeniable. He was the third highest-earning hedge fund manager of 2012 when he made $1.4 billion.

Steven Cohen has generally shied away from the press even before the SEC’s investigation making it difficult to truly understand his investment approach. However, Jack Schwager shared a rare look into Cohen’s process in 2003 when he published Stock Market Wizards: Interviews with America’s Top Stock Traders. Leading up to the interview with Cohen, Schwager highlighted that “in the seven years he has managed money, Cohen has averaged a compounded annual return of 45 percent.”

The ideas section of finbox.io tracks top investors and trending investment themes. You can get the latest data on the holdings discussed above at the Point72 Asset Management page.

As of this writing, I did not hold a position in any of the aforementioned securities and this is not a buy or sell recommendation on any security mentioned.

Expertise: Valuation, financial statement analysis. Matt Hogan is also a co-founder of finbox.io. His expertise is in investment decision making. Prior to finbox.io, Matt worked for an investment banking group providing fairness opinions in connection to stock acquisitions. He spent much of his time building valuation models to help clients determine an asset’s fair value. He believes that these same valuation models should be used by all investors before buying or selling a stock. His work is frequently published at InvestorPlace, Benzinga, ValueWalk, AAII, Barron’s, Seeking Alpha and investing.com. Matt can be reached at matt@finbox.io or at +1 (516) 778-6257.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.